Better defining the factors that regulate GLO-2 activity in vivo could lead to novel dietary or pharmacological strategies to reduce MGO accumulation and thereby mitigate the development of diabetes and its cardiovascular complications. This evidence concerns the gene HAGH and diabetes mellitus.